Here we show that such dual inhibition of VEGFR2 and CDK1 kinase activity perturbs proliferation of breast cancer cells and is a potent anti-angiogenic agent, both in vitro and in an ex vivo murine model. The gene discussed is KDR; the disease is breast carcinoma.